AR020055A1 - Una composicion farmaceutica o cosmetica que contiene una sustancia de esmalte activa, usos de dicha composicion y un metodo para preparar la misma. - Google Patents

Una composicion farmaceutica o cosmetica que contiene una sustancia de esmalte activa, usos de dicha composicion y un metodo para preparar la misma.

Info

Publication number
AR020055A1
AR020055A1 ARP990100872A ARP990100872A AR020055A1 AR 020055 A1 AR020055 A1 AR 020055A1 AR P990100872 A ARP990100872 A AR P990100872A AR P990100872 A ARP990100872 A AR P990100872A AR 020055 A1 AR020055 A1 AR 020055A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical
substance
composition
prepare
same
Prior art date
Application number
ARP990100872A
Other languages
English (en)
Original Assignee
Straumann Inst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Straumann Inst Ag filed Critical Straumann Inst Ag
Publication of AR020055A1 publication Critical patent/AR020055A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Preparations (AREA)

Abstract

Una Composicion farmacéutica o cosmética que contiene una sustancia de esmalte activa, composicion que comprende una sustancia de esmalte activaseleccionada del grupo formado por matriz de esmalte, derivados de matriz de esmalte y/o proteínas de matriz de esmalte. La composicion farmacéutica ocosmética de esta invencion puede ser usada para cicatrizar una herida, mejorar la cicatrizacion de una herida, regenerar o reparar tejidos blandos o preveniry/o tratar una infeccion. Método para la preparacion de dichas composiciones farmacéuticas o cosméticas.
ARP990100872A 1998-02-27 1999-03-02 Una composicion farmaceutica o cosmetica que contiene una sustancia de esmalte activa, usos de dicha composicion y un metodo para preparar la misma. AR020055A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK27098 1998-02-27
DKPA199801328 1998-10-16

Publications (1)

Publication Number Publication Date
AR020055A1 true AR020055A1 (es) 2002-04-10

Family

ID=34395112

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100872A AR020055A1 (es) 1998-02-27 1999-03-02 Una composicion farmaceutica o cosmetica que contiene una sustancia de esmalte activa, usos de dicha composicion y un metodo para preparar la misma.

Country Status (6)

Country Link
US (3) US6503539B2 (es)
JP (1) JP4726296B2 (es)
AR (1) AR020055A1 (es)
BR (1) BRPI9908182C1 (es)
PL (1) PL204797B1 (es)
RU (1) RU2241489C2 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2640994C (en) * 1998-02-27 2013-07-09 Biora Bioex Ab Enamel matrix protein composition for preventing or treating infection
US6884427B1 (en) * 1999-02-08 2005-04-26 Aderans Research Institute, Inc. Filamentary means for introducing agents into tissue of a living host
US20030096740A1 (en) * 1999-03-10 2003-05-22 Lars Hammarstrom Matrix protein compositions for induction of apoptosis
US6979670B1 (en) * 1999-03-10 2005-12-27 Biora Bioex Ab Matrix protein compositions for grafting
ATE285821T1 (de) * 1999-10-08 2005-01-15 Affinium Pharm Inc Fab i inhibitoren
US6821953B1 (en) * 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
DE60140191D1 (de) * 2000-06-20 2009-11-26 Straumann Inst Ag Zusammensetzungen mit matrixproteinen zur regeneration von dentin
US7304030B2 (en) * 2000-06-20 2007-12-04 Biora Ab Matrix protein composition for dentin regeneration
EP1309361A1 (en) * 2000-08-08 2003-05-14 Bioamide, Inc. Scaffolds for tissue engineered hair
US7144729B2 (en) 2000-09-01 2006-12-05 Dfb Pharmaceuticals, Inc. Methods and compositions for tissue regeneration
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
CA2434254C (en) * 2001-01-12 2013-08-13 Board Of Regents, The University Of Texas System Novel antiseptic derivatives with broad spectrum antimicrobial activity for the impregnation of surfaces
US7033611B2 (en) * 2001-02-23 2006-04-25 Biora Bioex Ab Matrix protein compositions for guided connective tissue growth
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
PL369029A1 (en) * 2001-09-14 2005-04-18 Biora Bioex Ab Enamel matrix protein compositions for modulating immune response
EP1467673A4 (en) * 2002-01-23 2013-04-17 Dentsply Int Inc Irrigation solution and methods for use
US20040068284A1 (en) * 2002-01-29 2004-04-08 Barrows Thomas H. Method for stimulating hair growth and kit for carrying out said method
JP4948744B2 (ja) * 2002-10-04 2012-06-06 允 深江 歯周組織再生剤、その有効成分抽出法、およびプラスミド
EP1575951B1 (en) 2002-12-06 2014-06-25 Debiopharm International SA Heterocyclic compounds, methods of making them and their use in therapy
JP2004307454A (ja) * 2003-02-21 2004-11-04 Seikagaku Kogyo Co Ltd 生理活性ペプチド及びこれを含有する薬剤
US7494980B2 (en) * 2003-03-10 2009-02-24 The United States Of America As Represented By The Secretary Of The Army Antimicrobial peptide and methods of use thereof
US8778889B2 (en) * 2003-03-10 2014-07-15 The United States Of America As Represented By The Secretary Of The Army Antimicrobial decapeptide oral hygiene treatment
DE602004016831D1 (de) * 2003-03-17 2008-11-13 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
SI1644024T1 (sl) * 2003-06-06 2019-11-29 Univ Texas Protimikrobne raztopine za izpiranje
EP1641783B1 (en) * 2003-06-19 2012-03-28 Janssen Pharmaceutica NV Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
CA2576040A1 (en) * 2003-10-21 2005-04-28 Bioartificial Gel Technologies Inc. Hydrogel-containing medical articles and methods of using and making the same
US20050125033A1 (en) * 2003-12-04 2005-06-09 Mcnally-Heintzelman Karen M. Wound closure apparatus
US20050125015A1 (en) * 2003-12-04 2005-06-09 Mcnally-Heintzelman Karen M. Tissue-handling apparatus, system and method
CA2552911A1 (en) * 2004-01-20 2005-08-11 Board Of Regents, The University Of Texas System Methods for coating and impregnating medical devices with antiseptic compositions
US7597885B2 (en) * 2004-03-26 2009-10-06 Aderans Research Institute, Inc. Tissue engineered biomimetic hair follicle graft
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
EP2848614A3 (en) 2004-06-04 2015-07-29 Debiopharm International SA Acrylamide derivatives as antibiotic agents
AR050212A1 (es) * 2004-08-13 2006-10-04 Aderans Res Inst Inc Organogenesis a partir de celulas disociadas
RU2277933C2 (ru) * 2004-09-21 2006-06-20 Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Иммобилизованная форма цефазолина для профилактики послеоперационных инфекционных осложнений в оториноларингологии
US20060115782A1 (en) * 2004-11-30 2006-06-01 Chunhua Li Systems and methods for coating a dental appliance
US7766658B2 (en) * 2004-11-30 2010-08-03 Align Technology, Inc. Systems and methods for intra-oral diagnosis
US20060115785A1 (en) 2004-11-30 2006-06-01 Chunhua Li Systems and methods for intra-oral drug delivery
US7947508B2 (en) * 2004-11-30 2011-05-24 Align Technology, Inc. Systems and methods for intra-oral diagnosis
AU2005315253B2 (en) * 2004-12-10 2011-07-21 Straumann Holding Ag Protein formulation
SE0403014D0 (sv) * 2004-12-10 2004-12-10 Straumann Holding Ag New protein formulation
WO2006126096A2 (en) * 2005-04-09 2006-11-30 Makoto Fukae Effect of porcinesheath proteins on the regeneration activity of periodontal ligament
US20070048358A1 (en) * 2005-08-31 2007-03-01 Schorr Phillip A Antimicrobial substrates
US20070048356A1 (en) * 2005-08-31 2007-03-01 Schorr Phillip A Antimicrobial treatment of nonwoven materials for infection control
US20070048344A1 (en) * 2005-08-31 2007-03-01 Ali Yahiaoui Antimicrobial composition
US20070048345A1 (en) * 2005-08-31 2007-03-01 Kimberly-Clark Worldwide, Inc. Antimicrobial composition
WO2007062306A2 (en) 2005-11-18 2007-05-31 The Board Of Regents Of The University Of Texas System Methods for coating surfaces with antimicrobial agents
AR057628A1 (es) * 2005-11-22 2007-12-05 Aderans Res Inst Inc Injertos capilares derivados de cabello extirpado
US20070148138A1 (en) * 2005-11-22 2007-06-28 Aderans Research Institute, Inc. Hair follicle graft from tissue engineered skin
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
US20070135706A1 (en) * 2005-12-13 2007-06-14 Shimko Daniel A Debridement method, device and kit
US20070148187A1 (en) * 2005-12-27 2007-06-28 Intact Enterprises, Inc. Mastic gum composition for use as a dietary supplement in humans and animals
WO2008006083A2 (en) * 2006-07-07 2008-01-10 Surmodics, Inc. Beaded wound spacer device
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US7772213B2 (en) * 2006-07-27 2010-08-10 Nathan Strick Composition for the treatment of inflammatory conditions
US8623842B2 (en) * 2006-09-27 2014-01-07 Hemostasis, Llc Hemostatic agent and method
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
EP2120561A4 (en) 2007-02-19 2012-11-21 Plurogen Therapeutics Inc COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE
US7985537B2 (en) * 2007-06-12 2011-07-26 Aderans Research Institute, Inc. Methods for determining the hair follicle inductive properties of a composition
US20090202609A1 (en) * 2008-01-06 2009-08-13 Keough Steven J Medical device with coating composition
JP2012526840A (ja) * 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー 膜貫通送達のための製剤系
WO2010135449A1 (en) * 2009-05-19 2010-11-25 Plurogen Therapeutics, Inc. Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing
US9192626B2 (en) * 2009-06-10 2015-11-24 American Silver, Llc Dental uses of silver hydrosol
CN101991688A (zh) * 2009-08-20 2011-03-30 徐荣祥 药物组合物在制备治疗糖尿病溃疡药物中的用途
US8790613B2 (en) * 2010-02-24 2014-07-29 Erachem Comilog, Inc. Treated electrolytic manganese dioxide and method for its production
CA2801332C (en) 2010-10-15 2016-08-23 Straumann Holding Ag New emd formulation comprising pga
BR112013030381B1 (pt) 2011-05-27 2021-10-26 University Of Washington Through Its Center For Commercialization Produto de cuidado oral
SI2861608T1 (sl) 2012-06-19 2019-08-30 Debiopharm International Sa Derivati predzdravila (E)-N-metil-N-((3-metilbenzofuran-2-IL)metil)- 3-(7-okso-5,6,7,8-tetrahidro-1 ,8-nafthiridin-3-il)akrilamid
US20140023979A1 (en) * 2012-07-18 2014-01-23 Maha Mohamed Fouad Mounir Regeneration of ameloblast cells and dental enamel in vivo
WO2014062839A1 (en) 2012-10-16 2014-04-24 Surmodics, Inc. Wound packing device and methods
US20140186273A1 (en) * 2012-12-27 2014-07-03 University Of Southern California Chitosan -Amelogenin Hydrogel for In Situ Enamel Growth
US20140272803A1 (en) * 2013-03-14 2014-09-18 Alan Nevins Root canal for tissue in-growth
EP3001810B1 (en) * 2013-04-30 2020-03-11 Straumann Holding AG Trap 63
JP6483139B2 (ja) * 2014-01-17 2019-03-13 ストラウマン ホールディング アーゲー 増強した安定性のｅｍｄの製造方法
US10201457B2 (en) 2014-08-01 2019-02-12 Surmodics, Inc. Wound packing device with nanotextured surface
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
WO2016118644A1 (en) 2015-01-20 2016-07-28 Plurogen Therapeutics, Llc Compositions and methods of treating microbes
US9962465B2 (en) 2015-07-07 2018-05-08 University Of Southern California Amelogenin-chitosan hydrogel for dentin hypersensitivity
WO2017123986A1 (en) 2016-01-13 2017-07-20 University Of Washington Reagents and methods for mineralization of tooth enamel
JP6952353B2 (ja) 2016-01-31 2021-10-20 メディウーンド リミテッド 創傷を治療するためのデブリードマン組成物
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
BR112018071405A2 (pt) * 2016-04-18 2019-02-05 Mediwound Ltd métodos de debridamento de ferimentos crônicos
LT3923914T (lt) 2019-02-14 2023-07-25 Debiopharm International S.A. Afabicino kompozicija, jos gamybos būdas
CN113939306B (zh) 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途
US11457996B2 (en) * 2019-09-12 2022-10-04 King Abdulaziz University Dental pulp capping composition and method of preserving and regenerating capped pulp and dentin bridge
CZ308980B6 (cs) 2020-01-24 2021-11-03 Contipro A.S. Dentální přípravek z vláken na bázi kyseliny hyaluronové s regulovatelnou biodegradabilitou
US20240269167A1 (en) * 2020-12-21 2024-08-15 Biointelligent Technology Systems Slu A mucosal re-epithelialization composition
KR102802100B1 (ko) * 2023-07-14 2025-05-02 주식회사 티앤알바이오팹 흡수성 체내 지혈 키트 및 흡수성 체내 지혈제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU98529A1 (ru) * 1952-04-04 1953-11-30 Конструкторское Бюро Особое Рабочее колесо центробежного погружного насоса
SU1398869A1 (ru) * 1985-10-31 1988-05-30 Московский медицинский стоматологический институт им.Н.А.Семашко Способ лечени зв желудка и двенадцатиперстной кишки
SE454480B (sv) 1986-09-25 1988-05-09 Lars Hammarstrom Bindningsinducerande komposition
SE461313B (sv) 1988-03-17 1990-02-05 Biora Ab Bindningsinducerande komposition
SE503096C2 (sv) 1994-09-22 1996-03-25 Biora Ab Komposition innehållande EDTA för användning vid konditionering av tandrötter
EP0837880B1 (en) 1995-07-13 2005-08-17 Biora Ab Enamel matrix related polypeptide

Also Published As

Publication number Publication date
US20050271604A1 (en) 2005-12-08
BRPI9908182C1 (pt) 2021-05-25
PL204797B1 (pl) 2010-02-26
BRPI9908182B8 (pt) 2018-08-14
US20020169105A1 (en) 2002-11-14
US6720009B2 (en) 2004-04-13
JP2002504520A (ja) 2002-02-12
BRPI9908182B1 (pt) 2017-09-26
JP4726296B2 (ja) 2011-07-20
US6503539B2 (en) 2003-01-07
US20030064927A1 (en) 2003-04-03
US7294352B2 (en) 2007-11-13
RU2241489C2 (ru) 2004-12-10

Similar Documents

Publication Publication Date Title
AR020055A1 (es) Una composicion farmaceutica o cosmetica que contiene una sustancia de esmalte activa, usos de dicha composicion y un metodo para preparar la misma.
ATE220918T1 (de) Matrixprotein enthaltende zusammensetzungen zur wundheilung
ES2120274T3 (es) Utilizacion de un extracto de una bacteria filamentosa no fotosintetica y composicion.
DE60117043D1 (de) Behandlung von mukositis
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
MX9702415A (es) Extractos de cocoa antineoplastica y metodos para elaborar y usar los mismos.
BR0015604A (pt) Método para o tratamento de cicatrizes hipertróficas de modo a reduzir o tamanho e/ou melhorar a aparência das mesmas, composições para tratar condições adversas da pele, e, para reduzir o tamanho e melhorar a aparência de cicatrizes hipertróficas
NO952824L (no) Sterile gelsammensetninger for sårbehandling
DE60103894D1 (de) Sprühfähige wundversorgungszusammensetzung
MXPA02007059A (es) Composicion de autobronceado que contiene un ester n-acilado de aminoacido y un agente de autobronceado.
MX9710252A (es) Utilizacion de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento.
ES2181017T3 (es) Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol.
AU2001274374A1 (en) Matrix protein compositions for dentin regeneration
ES2102284T3 (es) Composicion cosmetica que comprende una asociacion de ceramidas y su utilizacion.
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
DE60135454D1 (de) Pharmazeutische gel-zusammensetzung
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
EP1361905B8 (en) Matrix protein compositions for guided connective tissue growth
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
AR004181A1 (es) El uso de porfirinas verdes para preparar una composicion farmaceutica para tratar desordenes del endometrio o para la esterilizacion y composicionesfarmaceuticas que las contienen.
UA42335A (uk) Спосіб лікування гнійних ран
AR027984A1 (es) Composicion para la higiene bucal que comprende clorhexidina como agente antibacteriano cationico para combatir la halitosis; uso de la clorhexidina para preparar dichas composiciones y procedimiento para tratar la halitosis, utilizando dichas composiciones para la higiene bucal
UY24489A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimiento para su preparación y aplicación de estos compuestos en medicamentos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure